Pharmacogenetics of thiazolidinedione therapy

被引：13

作者：

Aquilante, Christina L. ^{[1
]}

机构：

[1] Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA

来源：

PHARMACOGENOMICS | 2007年 / 8卷 / 08期

关键词：

pharmacoagenecics; pharmacogenomics; pioglitazone; rosightazone; thiazolidinedione; troglitazone;

D O I：

10.2217/14622416.8.8.917

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The thiazoliclinediones (TZDs) are peroxisome proliferator-activated receptor-gamma, agonists and have glucose-lowering, insulin-sensitizing and anti-inflammatory effects. TZDs are approved for the treatment of Type 2 diabetes, and have been studied as a diabetes-prevention strategy. Despite widespread use of TZDs, a large number of patients fail to achieve a substantial reduction in glucose, or an improvement in insulin sensitivity, following treatment. Available data suggest that polymorphisms in genes encoding TZD drug targets, effector proteins and metabolizing enzymes contribute to the observed interindividual variability in TZD response and disposition. The purpose of this review is to highlight recent developments in the field of TZD pharmacogenetics, specifically focusing on clinical studies that have investigated genetic determinants of TZD response (i.e., reduction in glycemia and improvement in insulin sensitivity), disposition (i.e., pharmacokinetics), and side effects in patients with Type 2 diabetes and patients at risk for Type 2 diabetes.

引用

页码：917 / 931

页数：15

共 89 条

[51] Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease [J].

Menzaghi, Claudia ;

Trischitta, Vincenzo ;

Doria, Alessandro .

DIABETES, 2007, 56 (05) :1198-1209

[52]

Misbin RI, 1999, ANN INTERN MED, V130, P330, DOI 10.7326/0003-4819-130-4-199902160-00009

[53] Evidence for an important role of perilipin in the regulation of human adipocyte lipolysis [J].

Mottagui-Tabar, S ;

Rydén, M ;

Löfgren, P ;

Faulds, G ;

Hoffstedt, J ;

Brookes, AJ ;

Andersson, I ;

Arner, P .

DIABETOLOGIA, 2003, 46 (06) :789-797

[54] Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy - A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes [J].

Nathan, David M. ;

Buse, John B. ;

Davidson, Mayer B. ;

Heine, Robert J. ;

Holman, Rury R. ;

Sherwin, Robert ;

Zinman, Bernard .

DIABETES CARE, 2006, 29 (08) :1963-1972

[55] Thiazolidinedione use, fluid retention, and congestive heart failure [J].

Nesto, RW ;

Bell, D ;

Bonow, RO ;

Fonseca, V ;

Grundy, SM ;

Horton, ES ;

Le Winter, M ;

Porte, D ;

Semenkovich, CF ;

Smith, S ;

Young, LH ;

Kahn, R .

DIABETES CARE, 2004, 27 (01) :256-263

[56] Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone [J].

Neuschwander-Tetri, BA ;

Brunt, EM ;

Wehmeier, KR ;

Oliver, D ;

Bacon, BR .

HEPATOLOGY, 2003, 38 (04) :1008-1017

[57] Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes (vol 356, pg 2457, 2007) [J].

Nissen, Steven E. ;

Wolski, Kathy .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (24) :2457-2471

[58] Novel insulin sensitizers:: pharmacogenomic aspects [J].

Otto, C ;

Lehrke, M ;

Göke, B .

PHARMACOGENOMICS, 2002, 3 (01) :99-116

[59] Adverse hepatic and cardiac responses to rosiglitazone in a new mouse model of type 2 diabetes: Relation to dysregulated phosphatidylcholine metabolism [J].

Pan, Huei-Ju ;

Lin, Yiming ;

Chen, Yuqing E. ;

Vance, Dennis E. ;

Leiter, Edward H. .

VASCULAR PHARMACOLOGY, 2006, 45 (01) :65-71

[60] The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects [J].

Pedersen, Rasmus S. ;

Damkier, Per ;

Brosen, Kim .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (06) :682-689

← 1 2 3 4 5 6 7 8 9 →